Reid Robison, a psychiatrist and psychedelic-assisted therapy key opinion leader. Instead, in July, Novamind acquired Cedar Psychiatry, co-founded by Dr. “We’re not looking to start from zero to develop the psychedelic-assisted therapy clinics of the future, and hiring new doctors and developing new protocols.” Conforti suggests, adding that Novamind’s entry into that space is different from other entrants. “Ketamine is, effectively, the first legal psychedelic,” Mr. The clinical care pillar focuses on ketamine-assisted therapy as well as other innovative therapies. ![]() Novamind is focused on three pillars: clinical care, clinical research and a retreat network. The inflection point has already happened – the infrastructure of tomorrow is being built today.” He believes that MDMA could be a prescription medicine within the next 24 months, “which sounds like a long time, but you need to get a network of trained individuals to administer these treatments according to evidence-based protocols. ![]() Conforti points to more than one-hundred clinical trials currently being conducted to evaluate the use of psychedelics for the treatment of mental health disorders, particularly a Phase 3 trial being conducted by the Multidisciplinary Association for Psychedelic Studies, or MAPS, assessing 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for the treatment of post-traumatic stress disorder. ![]() This unmet need remains core to our vision: we’re working toward a new standard of mental health care.” “As an example, 30% of cases of depression are not responsive to standard treatments. “We saw an opportunity to build a sustainable business in a market that’s going to grow very quickly, especially given the rate of treatment-resistant conditions,” Yaron Conforti, Novamind’s CEO, says in an interview with BioTuesdays. Closely-held Novamind is building the infrastructure required to facilitate safe, legal and medically-supervised psychedelic-assisted therapy.
0 Comments
Leave a Reply. |